Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Contract IDV Awards
Indefinite Delivery Contract HHSN272201000030I
Award Date
3/22/10
Last Date to Order
3/21/17
Overview
Contacts
5
Activity
2
Contract IDVs
Contract Awards
7
Subawards
Transactions
2
Price Lists
Opportunity Stack
Similar IDVs
Federal Agency
NIAID DEA OA Acquisitions
Awardee
University Of Georgia Research Foundation, Inc. NMJHD63STRC5
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
PSC Category
AN11 - Health R&D Services; Health Care Services; Basic Research
Federal Contract Vehicle
NIAID Animal Models of Infectious Diseases 2010-2017
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
NIAID Animal Models of Infectious Diseases 2010-2017
Master IDIQ
HHSN272201000030I
Indefinite Delivery Contract
7
Federal Contract Awards
Update #1
Update #2
Update #3
Update #4
BIOMEDICAL (BASIC)
Posted 3/22/10
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
1
TAS::75 0885::TAS
Other Administrative Action
$0
3/15/11
Not listed
BIOMEDICAL (BASIC)
Not listed
$0
3/22/10
5
1
2
Name
Description
Awardee
Potential Value
AwardDate
CompletionDate
Updated At
Delivery Order HHSN272201000030I-HHSN27200001
TAS::75 0885::TAS ANIMAL MODELS OF INFECTIOUS DISEASES
University Of Georgia Research Foundation, Inc.
$13.7m
3/22/10
8/31/17
4/4/19
Delivery Order HHSN272201000030I-HHSN27200006
The U.S. Department of Health and Human Services, National Institute of Allergy and Infectious Diseases (NIAID) awarded a Delivery Order contract to the University of Georgia Research Foundation, Inc. (UGA Research Foundation) for "ANIMAL MODELS OF INFECTIOUS DISEASES". This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) awarded to UGA Research Foundation in July 2024, valued up to $146.3 million over 7 years. The contract focuses on developing and employing animal and animal replacement models to support NIAID's pandemic preparedness efforts, covering small animal models, non-human primate models, animal replacement and non-traditional animal models, and specialized reagents generation. The current Delivery Order has a ceiling value of $250,376.00 and was awarded on June 22, 2016 with an ultimate completion date of August 31, 2017. The award does not have a set-aside designation.
University Of Georgia Research Foundation, Inc.
$250.4k
6/22/16
8/31/17
11/6/17
Delivery Order HHSN272201000030I-HHSN27200003
This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. Department of Health and Human Services, to the University of Georgia Research Foundation, Inc. (UGA Research Foundation) as the prime contractor. The contract, titled "ANIMAL MODELS OF INFECTIOUS DISEASES," has a ceiling value of $225,672.00 and was awarded on September 1, 2013 with a completion date of August 31, 2014. The contract is a Delivery Order under the NIAID Animal Models of Infectious Diseases 2010-2017 Indefinite Delivery Contract (IDC), and is for firm fixed-price services. The contract requires the UGA Research Foundation to provide animal models and related research services to support NIAID's infectious disease research programs. A subcontract was awarded to the University of Wisconsin Oshkosh to produce and distribute specialized reagents. This contract does not have a set-aside designation. The UGA Research Foundation has extensive experience executing federal awards from agencies like the National Institutes of Health, supporting a wide range of research and development activities.
University Of Georgia Research Foundation, Inc.
$225.7k
9/1/13
8/31/14
8/15/13
Delivery Order HHSN272201000030I-HHSN27200004
This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to the University of Georgia Research Foundation, Inc. (UGA Research Foundation). The $211,731 Firm Fixed Price Delivery Order falls under the NIAID Animal Models of Infectious Diseases 2010-2017 Indefinite Delivery Contract (IDC), which has a ceiling value of up to $146.3 million over 7 years. The contract is focused on developing and employing animal and animal replacement models of infectious diseases to support NIAID's pandemic preparedness efforts. The four main task areas are: small animal models, non-human primate models, animal replacement and non-traditional animal models, and generation of specialized reagents. This contract positions UGA Research Foundation to play a key role in evaluating therapeutics, vaccines, and diagnostics for priority infectious diseases, including emerging viral threats and antimicrobial resistant infections. The University of Wisconsin Oshkosh is a subcontractor performing work on maintaining the A.viteae life cycle and distributing research materials.
University Of Georgia Research Foundation, Inc.
$211.7k
7/18/14
8/31/15
7/18/14
Delivery Order HHSN272201000030I-HHSN27200007
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, to the University of Georgia Research Foundation, Inc. (UGA Research Foundation). The contract, titled "ANIMAL MODELS OF INFECTIOUS DISEASES," has a ceiling value of $779,623.63 and is a delivery order under the NIAID Animal Models of Infectious Diseases 2010-2017 indefinite delivery contract (IDC). The contract does not have a set-aside designation. Under this award, UGA Research Foundation will provide animal models and related services to support NIAID's research on infectious diseases and pandemic preparedness. This contract award builds on UGA Research Foundation's extensive experience executing federal research and development contracts, including previous work for agencies such as the National Oceanic and Atmospheric Administration, Department of Defense, and Federal Highway Administration.
University Of Georgia Research Foundation, Inc.
$779.6k
3/20/17
2/28/18
3/22/22
5
1
Name
Description
Solicitation Number
FederalAgency
Type
PostedDate
Animal Models of Infectious Diseases
Added: Sep 12, 2008 2:22 pm The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAIDs Division of Microbiology and Infectious Diseases (DMID) has a requirement to provide and develop animal models in order to advance our understanding of infectious diseases as well as advance the development of therapeutics and vaccines for infectious diseases. NIAIDs role in developing medical products to counter emerging, re-emerging and other infectious diseases, as well as agents of bioterrorism, is part of a larger national strategy, involving multiple governmental agencies. As such, NIAID supports integrated efforts in basic and applied research, product development, and technology development based on national priorities for medical products. Since 2001, NIAID has established a comprehensive infrastructure with extensive resources that support all levels of biodefense research. With this solid framework of research and product development resources for biodefense in place, NIAID is now transitioning this infrastructure to provide the flexibility required to meet the challenges of emerging, re-emerging and other infectious diseases in addition to biodefense. The use of animal models helps advance our understanding of infectious diseases as well as the development of therapeutics and vaccines. For example, animal models are used to evaluate product candidates; provide data in support of Investigational New Drug (IND) applications; guide the selection of human dose levels and the design of clinical studies/trials; and provide pivotal efficacy data for products to be licensed under FDAs Animal Efficacy Rule (21 CFR 314.610 and 601.91), when clinical trials are not ethical or feasible. In addition, for emerging and rare diseases, understanding the disease in animals may provide relevant information when little can be learned directly from humans. Therefore, DMID is committed to developing and providing animal models to benefit the research community and public health. For the most part, animal model services are currently provided tough multiple, specialized programs. DMID now seeks to adopt an integrated approach to the provision of services by creating unified, comprehensive, coordinated programs. This strategy is being employed to: advance science by promoting cross-fertilization across and within disciplines and approaches; serve the research community more conveniently; achieve efficient use of resources tough economy of scale and avoidance of duplication; and provide the flexibility needed to respond to changing priorities. Accordingly, DMID is establishing the Animals Models of Infectious Diseases program, utilizing the Indefinite Delivery, Indefinite Quantity (IDIQ) contract mechanism. Under IDIQ contracts, base contract awards are made to multiple offerors that successfully propose a general approach to the technical requirements of the solicitation, providing a guaranteed minimum award. Task orders for specific tasks requiring specialized expertise are solicited and funded within the program Contractor pool. DMID is replacing multiple pathogen or class specific solicitations with one broad IDIQ solicitation for multiple contracts to cover all areas of current and potential future interests. Animal models currently covered by existing pathogen-specific contracts will not be re-competed separately upon completion; however, they could be awarded as task orders under this program, upon expiration of those contracts. DMID is also establishing the Microbiology and Infectious Diseases Biological Research Resources (MID-BRR) program, which will serve as a central repository for microbiology and infectious disease researchers. The Animal Models of Infectious Diseases program will ensure a supply for the MID-BRR of pathogens that must be grown in animals and reagents integral to research on these organisms. The Technical Requirements will be assembled into the following sections: o General Statement of Work, which specifies the basic technical requirements for all contracts. o Part Statements of Work, which specify additional technical requirements for contracts awarded to support each of four specific Parts: Part A Small Animal Models Part B GLP Small Animal Models Part C Non-Human Primate Models (+/- GLP) Part D Nontraditional Animal Models (+/- GLP) Offerors may propose in response to one or more Part(s) of their choosing, and are not expected to respond to all Parts. Offerors are also not expected to be responsible for all pathogens of interest or within scope for these contracts. Offerors responding to multiple Parts must provide separate Technical and Business Proposals for each Part. Proposals for each Part will be reviewed independently. For the purposes of this contract:  Small animals (Parts A and B) are defined as traditional small laboratory animal species, such as mice, rats, guinea pigs, hamsters, ferrets, chinchillas, and rabbits.  Non-human primates (Part C) include various species, such as macaques, including Chinese and Indian rhesus macaques (Macaca mulatta), cynomyologous macaques (Macaca fascicularis), and pig-tailed macaques (Macaca nemestrina), etc. Excluded are baboons and chimpanzees.  Nontraditional animals (Part D) are defined as specialty laboratory animal species not covered in Small Animal or Non-Human Primate Models (Parts A C), which may have requirements not met in typical biomedical laboratory animal facilities, such as armadillos, woodchucks, snails, other invertebrates, and goats, swine, horses, cattle, etc.  Products to be evaluated in these animal models are broadly defined to include vaccines and other prevention strategies (e.g. microbicides), therapeutics targeting the host or the pathogen, including immunotherapeutics, and diagnostics. Products will be provided to the Contractor by the Project Officer or a third party after Project Officer approval.  Pathogens of interest must be pathogens of human concern and not only of animal concern; however surrogate human pathogen/animal combinations may be used for diseases where human pathogens cannot be studied in animal models.  Pathogens are defined as bacteria, viruses, parasites, fungi, toxins, and other agents such as prions, including NIAID Category A, B and C Priority Pathogens (http://www3.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/CatA.htm).  Reagents are defined as biochemical, genomic, molecular, cellular, and immunologic materials integral to research on these pathogens. The following factors will be considered when evaluating proposals: Technical Capability: adequacy and appropriateness of the general technical approach to animal model studies, to include conduct of product efficacy studies, animal model development, and supportive measurements (immunological, pharmacological, clinical, pathological, etc.); technical approach to pathogen production and characterization, including overall understanding of the pathogen and its behavior in animal models. In addition, capability to comply with Good Laboratory Practices (21 CFR Part 58) will be evaluated for Part B, Part C and Part D. Personnel and Project Management: adequacy, appropriateness and relevance of expertise, experience, qualifications, and availability of the key professional and technical staff with a project of similar size, scope, and complexity; adequacy and appropriateness of proposed organization and staffing to ensure efficient planning, initiation, implementation, conduct, and completion of all activities, including plans for communication and sharing of research resources. Facilities, Equipment and other Resources: availability of adequate, accredited animal facilities, with biocontainment appropriate for the pathogens proposed; availability of equipment necessary for the proposed animal studies; and adequacy of institutional biosafety program. It is anticipated that multiple cost reimbursement, completion type contracts will be awarded for a seven-year period of performance beginning on or about January 4, 2010. Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about September 29, 2008, and may be accessed tough FedBizOpps http://www.fedbizopps.gov/. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. See Government-Wide Numbered Note 26.
NIH-NIAID-DMID-AI2008041
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
9/12/08, 2:22 PM